Status: Recruiting
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC
The purpose of this study is to test whether or not number of circulating cancer cells detected in the blood can be decreased the by combining the standard treatment (durvalumab) with Tremelimumab and additional chemotherapy
Participants needed: 48
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Maximilian DiehnUpdated: May 4, 2026Locations: 1
Eligibility criteria
Histologically- or cytologically-documented NSCLC presenting with locally-advanc... [+15]
Subjects with Grade ≥ 2 neuropathy will be evaluated on a case by case basis aft... [+18]